Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.76 |
| ▸ | MEN1 | O00255 | 5/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
| ▸ | ATM | Q13315 | 1/20 | 0.76 |
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | P4HB | P07237 | 2/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.64 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31643319 | 0.88 | KMT2A (0.67) | KDM4EKMT2AMEN1MAPTATM | |
| SCHEMBL18192052 | 0.87 | LMNA (0.72) | KDM4EKMT2AMEN1POLBLMNA | |
| SCHEMBL4864670 | 0.85 | L3MBTL1 (0.77) | KDM4EKMT2AMEN1MAPTPOLB | |
| SCHEMBL26102667 | 0.85 | LMNA (0.69) | KDM4EKMT2AMEN1MAPTPOLB | |
| SCHEMBL17779707 | 0.84 | KMT2A (0.83) | KDM4EKMT2AMEN1POLBP4HB | |
| SCHEMBL16361371 | 0.84 | P4HB (0.78) | KDM4EKMT2AMEN1MAPTATM | |
| SCHEMBL3317836 | 0.84 | LMNA (0.68) | KDM4EKMT2AMEN1MAPTATM | |
| SCHEMBL4503126 | 0.83 | KMT2A (0.62) | KDM4EKMT2AMEN1MAPTATM | |
| SCHEMBL17775629 | 0.83 | KMT2A (0.86) | KDM4EKMT2AMEN1POLBLMNA | |
| SCHEMBL12540892 | 0.83 | CYP2D6 (0.59) | KDM4EKMT2AMEN1MAPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507239-B1 | AZACYCLIC SPIRO DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-03-13 | — | — | EP | disclosed |
| EP-2507239-B1 | AZACYCLIC SPIRO DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-03-13 | — | — | EP | disclosed |
| US-20150148363-A1 | NEW AZACYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-05-28 | — | — | US | disclosed |
| US-20150148363-A1 | NEW AZACYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-05-28 | — | — | US | disclosed |
| US-20150148363-A1 | NEW AZACYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-05-28 | — | — | US | disclosed |
| US-20140005400-A1 | NEW AZACYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2014-01-02 | — | — | US | disclosed |
| EP-2430023-B1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-12-11 | — | — | EP | disclosed |
| US-8552024-B2 | Azacyclic compounds | HOFFMAN-LA ROCHE INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8552024-B2 | Azacyclic compounds | HOFFMAN-LA ROCHE INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8552024-B2 | Azacyclic compounds | HOFFMAN-LA ROCHE INC. (US) | 2013-10-08 | — | — | US | disclosed |
| EP-2430023-A1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-03-21 | — | — | EP | disclosed |
| WO-2012020035-A1 | NEW AZACYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | disclosed |
| US-20120041013-A1 | NEW AZACYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | US | disclosed |
| US-20120041013-A1 | NEW AZACYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | US | disclosed |
| US-20120041013-A1 | NEW AZACYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | US | disclosed |
| WO-2011067166-A1 | AZACYCLIC SPIRO DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011067166-A1 | AZACYCLIC SPIRO DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20110130417-A1 | NEW AZACYCLIC DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-06-02 | — | — | US | disclosed |
| WO-2010130665-A1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292212-A1 | NEW AZACYCLIC DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130417-A1 | NEW AZACYCLIC DERIVATIVES | AZI2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, UGT1A1 | KDM4E 817/4885KMT2A 1130/4885MEN1 379/4885 |
| US-20140005400-A1 | NEW AZACYCLIC COMPOUNDS | LIPE, GPR119, LIPC | KDM4E 416/4885KMT2A 1650/4885MEN1 2151/4885 |
| US-20100292212-A1 | NEW AZACYCLIC DERIVATIVES | GPR119, LDLR, LPL | KDM4E 905/4885KMT2A 830/4885MEN1 2464/4885 |
| US-20120041013-A1 | NEW AZACYCLIC COMPOUNDS | LIPE, GPR119, LIPC | KDM4E 416/4885KMT2A 1650/4885MEN1 2151/4885 |
| US-20150148363-A1 | NEW AZACYCLIC COMPOUNDS | LIPE, GPR119, LIPC | KDM4E 416/4885KMT2A 1650/4885MEN1 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.